Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Moonwalk Biosciences in the transaction. Moonwalk Biosciences announced it had completed the Series A and Seed financings totaling $57 million....
Moonwalk Biosciences’ $57 Million Series A Financing Round
Remix Therapeutics’ $60 Million Financing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Remix Therapeutics in the transaction. Remix Therapeutics announced it closed its $60 million financing led by The Column Group. The...
Remix Therapeutics’ Collaboration Agreement With Roche
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Remix Therapeutics in the transaction. Remix Therapeutics (Remix), a clinical stage biotechnology company, announced it had entered into...
Seattle Children’s Launch of BrainChild Bio
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented BrainChild Bio in the deal. Seattle Children announced the launch of BrainChild Bio to accelerate CAR T-cell therapies for...
Solu Therapeutics’ $31 Million Seed Financing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Solu Therapeutics in the transaction. Solu Therapeutics announced the closing of an oversubscribed $31 million seed financing co-led...
RIGImmune’s Acquisition of Subintro
Gunderson Dettmer represented RIGImmune on the deal. RIGImmune, a biopharmaceutical company developing a new class of RNA immunotherapeutics, announced its acquisition of Subintro, a biotechnology company specializing...
Photys Therapeutics’ $75 Million Series A Financing
Gunderson Dettmer advised Photys Therapeutics on the deal. Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule (PHICS) medicines, announced its $75 million Series A financing...
Kernal Biologics’ $25 Million Series A Financing
Gunderson Dettmer represented Kernal Biologics on the deal. Kernal Biologics, a Massachusetts-based biotech company, announced its $25 million Series A financing led by Hummingbird Ventures with participation...
Carbon Biosciences’ $38 Million Series A Financing
Gunderson Dettmer represented Carbon Biosciences on the deal. Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, announced its emergence from stealth mode and the closing of...
GSK’s $3.3 Billion Acquisition of Affinivax
Davis Polk advised GSK plc on the deal while Gunderson Dettmer represented Affinivax. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront...
Remix Therapeutics’ $70 Million Series B Financing
Gunderson Dettmer advised Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite...
Remix Therapeutics’ Collaboration Agreement with Janssen Pharmaceutica NV
Gunderson Dettmer represented Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical...